CAR T therapy for GPC3-positive pediatric solid tumors
Part of Cancer, Digestive system, Genetic & congenital, Kidney & urinary, Women’s health & pregnancy clinical trials.
This Phase 1 study tests a customized immune-cell treatment (CAR T cells) made to recognize GPC3, a marker found on some tumors. It’s designed for children and young people whose solid tumors have not been cured by standard treatment and who can safely receive this therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child’s tumor must be GPC3-positive based on lab testing of tumor tissue (enough cells and staining to count)
- Age 1 to 21 years, with a life expectancy of at least 16 weeks
- They must be well enough overall (Lansky/Karnofsky score 60% or higher)
- If the tumor is liver cancer (hepatocellular carcinoma), it must match certain liver-stage criteria and a Child-Pugh score under 7
- Blood counts and organ tests must be strong enough (for example: neutrophils, platelets, hemoglobin, kidney function, oxygen level)
- No pregnancy or breastfeeding; if sexually active, they must use reliable birth control for 6 months after the T-cell infusion
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of immunotherapy called CAR T cells that are trained to find and attack cancer cells with a specific marker (GPC3). The CAR T cells are also 'armored' with extra proteins (IL-15 and IL-21) to help them work better. It might be an option for adults with advanced solid tumors, especially liver cancer, that have not responded to standard treatments.
This study tests a new kind of immune therapy called CAR T-cells that are specially designed to find and attack cancer cells that carry a protein called GPC3. Researchers want to see if this treatment is safe and helpful for people with solid tumors that have not responded to standard therapies.
This trial tests a new kind of immunotherapy for children and teens with solid tumors that have not responded to standard treatments. The therapy uses specially engineered T cells (CAR T cells) that target a protein called GPC3 found on many tumor cells, and it includes extra signals (IL-15 and IL-21) to help the T cells work better.
This early-phase study tests a lab-made immune therapy (CAR T cells) made from your own cells to treat children’s solid tumors that have a specific marker called B7-H3. It is designed for kids whose cancer has come back or did not respond to standard treatment, aiming to shrink tumors and keep the therapy safe.
This trial tests a new type of immune cell therapy called CAR T cells that are designed to recognize and attack cancer cells in children and young adults with certain solid tumors that have come back or not responded to standard treatment.
This trial tests whether a special type of immune cell (called CAR T cells) can fight a brain tumor called glioblastoma that has come back. The cells are made to target a protein on the tumor cells, and the study will see if this treatment is safe and helpful.
Hear when a new Liver Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.